FeNO testing can help with the selection of a personalised, targeted therapy by identifying appropriate candidates for biologic treatments.1
Key highlights:
Only 20% of patients with poor symptom control despite high-dose treatment, have severe asthma.2
Patients with persistent high FeNO are likely to have severe asthma.3
A FeNO suppression test, can help determine whether a patient on ICS has been adherent with therapy.4
Asthma can be serious
Left untreated, asthma of all severities can become out of control. Patients with uncontrolled asthma usually have high FeNO, a trait associated with up to 3.2x greater risk of exacerbations when compared to low FeNO levels, faster decline in lung function and long-term airway remodelling.1-3
Uncontrolled asthma4
Patients have uncontrolled asthma if at least one of the following applies:
- Poor symptom control: frequent symptoms or reliever use, activity limited by asthma, night waking due to asthma
- Frequent exacerbations (≥2/year) requiring oral corticosteroids (OCS) or serious exacerbations (≥1/year) requiring hospitalisation
UP TO 50% FEWER
EXACERBATIONS
with FeNO-guided asthma management
for both adults and children10
FeNO testing makes a difference
FeNO testing helps healthcare professionals be more confident with their asthma diagnosis. Introducing FeNO testing is an effective way to start your newly diagnosed asthma patients on the right track to asthma control.
Find patients likely to respond to ICS
FeNO is sensitive to inhaled corticosteroids (ICS): high FeNO levels indicate the patient is likely to respond. This can help titrate the first ICS prescription. In contrast, it is unlikely that ICS will help control asthma in patients whose FeNO is low.8 Around 15% of asthmatics, typically middle-aged, overweight women, will not respond to ICS as expected.1,11
Help patients help themselves
FeNO testing is praised by many healthcare professionals as a great educational tool. Seeing their FeNO value helps patients understand the degree of airway inflammation in their lungs and the associated risks. Watching their FeNO come down to a healthier level is encouraging and may help patients with compliance to ICS medication.
Save time with FeNO
FeNO testing is a safe procedure that can easily be included in your clinical routine. It takes less than two minutes to perform a FeNO test and see the results at the point-of-care. FeNO advocate Dr Richard Russell (UK) describes it as a "desktop test", with the device available within arm's reach.
Why measure FeNO?
FeNO testing is the most convenient way to assess airway inflammation at the point-of-care.
Simple
One test, one number. Airway inflammation in a single FeNO level.
Immediate
Performing a FeNO test takes approximately one minute - quicker than making a cup of coffee.
Non-invasive
Taking a FeNO test is as simple as inhaling and exhaling: no blood, sweat or tears required.
Ready for FeNO by NIOX®?
Request a quote for a device today with our simple and easy to use quotation tool. Used by thousands of healthcare professionals, NIOX® is the global device of choice for FeNO testing.
Request a Quote
NIOX® Customer Support and Training
At NIOX® we are passionate about providing excellent support and training.
References:
1. Busse, W.W et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. The Lancet Respir Med. 2021:9(10): pp.1165-1173.
2. Bai TR et al. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J. 2007;30(3):452-6.
3. Matsunaga K et al. Persistently high exhaled nitric oxide and loss of lung function in controlled asthma. Allergol Int. 2016;65(3):266-71.
4. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2021 update.
5. Heaney LG et al. Medical Research Council UK Refractory Asthma Stratification Programme (RASP-UK). Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma. Am J Respir Crit Care Med. 2019;199(4):454-464.
6. Dweik RA et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602-15.
7. Holguin F et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588.
8. Corren J et al. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol Pract. 2020;8(2):516-526.
9.NIOX®. Data on File; MKT-DOF-007. 2023.